PMID: 11322207Apr 27, 2001Paper

Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial

Journal of Hepatology
A MangiA Andriulli

Abstract

In chronic hepatitis C the schedule of interferon (IFN), 3 MU thrice weekly (tiw) plus ribavirin (1000-1200 mg/daily) needs further evaluation, as IFN dosages >3 MU achieve better responses. To compare the efficacy of 5 MU tiw of IFN with (96 patients) or without ribavirin (96 patients) for 12 months in naïve patients, to evaluate the effect of baseline features on the response to therapy, and to determine a reliable point in time during treatment to predict non-response. Sustained virologic response was 20.8% (95% CI 13-29) with IFN monotherapy and 54.2% (95% CI 44-64) with combination (P = 0.0001), the relapse rate 39.4% (95% CI 23-56) and 9% (95% CI 1-16) (P = 0.0007), and the combined rate of sustained biochemical and virologic response 22.7% (95% CI 14-31) and 60.5% (95% CI 50-71) (P = 0.0001), respectively. Patients given combination therapy were more likely to respond regardless of baseline features. Apart from genotype non-1, predictive factors for IFN monotherapy were ineffective in predicting response to combination therapy. Using logistic regression analysis, IFN-ribavirin was the strongest predictor of response (X2 = 21.3; P = 0.0001). Viral persistence at month 3 of therapy was a more accurate predictor than aminot...Continue Reading

References

Apr 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P J ScheuerG M Dusheiko
Jun 1, 1997·Journal of Hepatology·A MangiaA Andriulli
Jul 1, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·N P LamT J Layden
Dec 16, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M J TongA Conrad
Aug 29, 1998·Journal of Hepatology·M Martinot-PeignouxP Marcellin

❮ Previous
Next ❯

Citations

Jan 8, 2009·International Journal of Technology Assessment in Health Care·Debbie Hartwell, Jonathan Shepherd
Oct 24, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Stefan WirthPatrick Gerner
Oct 31, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kelly A GeboEric B Bass
Oct 31, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Geetanjali ChanderKelly A Gebo
Sep 13, 2003·Journal of Viral Hepatitis·N C TassopoulosUNKNOWN Hellenic Viral Hepatitis Research Network
Oct 13, 2006·Liver International : Official Journal of the International Association for the Study of the Liver·C P Day
Feb 19, 2004·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·D FestiG Marchesini
Nov 12, 2002·The American Journal of Gastroenterology·Stephen A HarrisonSteven Schenker
May 1, 2008·Current Diabetes Reports·Nimantha Mark Wilfred de Alwis, Christopher Paul Day
Sep 7, 2011·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Michelino Di Rosa, Lucia Malaguarnera
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Jesper BrokChristian Gluud
Jan 22, 2010·The Cochrane Database of Systematic Reviews·Jesper BrokChristian Gluud
Mar 16, 2012·The Cochrane Database of Systematic Reviews·Goran BjelakovicChristian Gluud

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.